Business Wire

APR Applied Pharma Research S.A. and Eris Pharmaceuticals (Australia) Pty Ltd. Announce the Signature of a License Agreement for the Distribution and Marketing of the HALYKOO Line in Australia and New Zealand

Del

APR Applied Pharma Research S.A. (“APR”), the independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products, and Eris Pharmaceuticals (Australia) Pty Ltd. (“Eris Pharma”), a leading pharmaceutical company, currently specialized in the development and marketing of healthcare products in Australia and the emerging markets, today announce the beginning of a partnership for the promotion, distribution and marketing of the Halykoo baby healthcare product line in Australia and New Zealand.

Thanks to this license agreement, APR records another success in widening its global network of partners for the brand Halykoo, which has been recently launched in Italy and will be rolled out in 2016 in several countries across the world, proving Halykoo high level of quality, innovation and appeal on an international basis.

This partnership will enable Eris Pharma to enter the pediatric market segment through the offer of the new and innovative brand, Halykoo - the first complete line of products including tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.

“We are proud to have the chance to launch the Halykoo range in Australia and New Zealand” – said Mr. Panos Athanasiou, CEO of Eris Pharma. “The HALYKOO brand will complement consistently the product portfolio of Eris Pharma, that currently covers a wide range of prescription medicine, OTC products, Medical Devices and skincare products, most of which are mainly addressed to adults. Adding the Halykoo products in our portfolio will enable us to bring to the Australian & New Zealand markets products targeting currently unaddressed needs of children from a very young age, providing the needed confidence and reassurance to their parents .

Eris Pharma Sales Director Mr. Karl Hansen asserted that “Halykoo represents a great opportunity to successfully compete in as valuable an area of the market as pediatric healthcare. Australian parents spend many billions of dollars each year ensuring the healthcare needs of their children are met, but are often confused in a congested marketplace. At the same time they are concerned about the ingredients in the products they buy, which is why the Halykoo range offers unique, innovative products that parents can trust. Eris Pharma is very excited to introduce Halykoo to Australian parents and is looking forward to playing a continuing role in their children’s health.”

Over the last 20 years, APR has developed high-quality products certified according to the strictest international regulations. “We are delighted to hail this partnership with Eris Pharma, which allows APR to enter new attractive overseas markets, Australia and New Zealand, and proves Halykoo internationally valuable positioning and potential” said Paolo Galfetti, CEO and co-founder of APR”. “We reckon that Eris Pharma is the right partner to introduce to caregivers and consumers an innovative and unique product option as Halykoo”.

About Halykoo

Halykoo is a new global brand in the pediatric self-care market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies.

Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies.

Halykoo products are the perfect combination of responsible, Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural BIO certified components), to careful dosing of the active principles and full compliance with the strictest safety standards - and the right delivery system for the right age.

For more info about Halykoo, please visit: www.halykoo.com

About Eris Pharmaceuticals (Australia) Pty Ltd

Eris Pharmaceuticals (Eris Pharma) was established in Australia in 2009 as a generic pharmaceuticals company. Today, Eris Pharma is an international leader in developing and distributing premium quality healthcare products in the generics, dermocosmetics, OTC and medical device categories. Eris Pharma’s focus is on premium products in numerous therapeutic categories that contain only the highest quality ingredients in specialised formulations.

Eris Pharma distributes its products to over 25 markets worldwide and has an aggressive plan to grow the business, focusing heavily on the Australian market. Underlying this ambition is Eris Pharma’s desire to form strong relationships that deliver only the best possible outcomes for customers and end users.

For more info about Eris Pharmaceuticals, please visit www.eris-pharma.com.au.

About APR Applied Pharma Research s.a.

APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch.

Contact information

Eris Pharmaceuticals (Australia) Pty Ltd
Panos Athanasiou; Chief Executive Officer
T.: +61 4 14143678 or email to p.athanasiou@eris-pharma.com
or
Karl Hansen; Sales Director - Australia and New Zealand
T.: +61 4 17062642 or email to k.hansen@eris-pharma.com
or
APR Applied Pharma Research s.a.
Paolo Galfetti; Chief Executive Officer
T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC for $115 Million18.7.2018 06:00Pressemelding

EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare disease, announced today that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland (Janssen) to acquire the global rights to SYLVANT® (siltuximab) for $115 million in cash. The transaction is subject to review under the United States Hart–Scott–Rodino Antitrust Improvements Act of 1976, as amended, and the parties expect to close following completion of this regulatory review period and the mutual satisfaction of other remaining closing conditions. SYLVANT® is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition. Idiopathic MCD is an inflammatory lymphoproliferative disorder, which causes the abnormal overgrowth of immune cells and shares many sym

The Best User Interface in Mobile and Web Tracking Just got Better18.7.2018 06:00Pressemelding

ThriveTracker, a leading web and mobile tracker for media buyers and performance marketers, today announced the general availability of its latest release featuring an all-new user interface (UI). Inspired by feedback from customers and partners, ThriveTracker designed the new UI to accelerate user adoption, improve usability and increase productivity. ThriveTracker focused on the user experience for all users regardless of device, (Desktop, Mobile, etc.), making it more intuitive and accessible. Improved navigation provides simplified access to frequently used functions in the platform, increases customer awareness of more advanced functionality and delivers fast access to detailed content when necessary. Cleaner, simpler, modern UI Clear, consistent navigation focuses your attention on where you are and what you can do Improved layout delivers common functions intuitively Simplified views provide faster access to relevant content Mobile Friendly Mobile responsive based on device New

JPMorgan Chase Bank announces the placement of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 202017.7.2018 19:40Pressemelding

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933) OR IN OR INTO JAPAN, THE PEOPLE’S REPUBLIC OF CHINA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. JPMorgan Chase Bank, N.A. (the “Issuer”) today announces the placement of cash-settled exchangeable bonds due 2020 (the “Bonds”) in aggregate principal amount of USD 350 million. The Bonds are referable to H-shares (the “Shares”) of Ping An Insurance (Group) Company of China Limited (the “Company”). Exchange rights in respect of the Bonds will be cash-settled only. The Bonds will be issued in principal amounts of USD 200,000 and integral multiples of USD 100,000 in excess thereof and will not bear interest. The Bonds will be issued with an issue price of 100% and will redeem at par on 30 December 2020. The initial exchange price (the “Initial Exchange Price”) will

Boston Capital Announces Closing of Boston Capital Income & Value U.S. Apartment Fund17.7.2018 14:00Pressemelding

Boston Capital, the third largest owner of apartments in the U.S. with over $19.6 billion invested, is pleased to announce the final investor closing of Boston Capital Income and Value U.S. Apartment Fund (“BCIV”). BCIV, a discretionary multi-investor Luxembourg based fund vehicle, includes financial institutions, insurance companies, pensions, and family offices among its investors and will acquire over $350 million in apartment properties throughout the U.S. “We are very pleased to close BCIV, the latest in a succession of institutional investment vehicles through Boston Capital’s conventional apartment investment arm, Boston Capital Real Estate Partners (“BCRE”),” said Jeff Goldstein, COO and Director of Real Estate at Boston Capital. The Fund generates high current dividends and capital growth by acquiring and renovating Class B apartment properties located in major and secondary U.S. markets and by targeting a renovated rental price point well below new construction rates, which a

Amobee Wins Auction Process to Acquire Videology Assets17.7.2018 13:13Pressemelding

Singtel subsidiary Amobee, a leading global digital marketing technology company serving brands and agencies, today announced that it has emerged as the winner in the court supervised auction to acquire certain assets from Videology, a software provider for advanced TV and video advertising, for purchase price of approximately US$101 million1. The purchase price is subject to adjustments for accounts receivable at closing, estimated to be approximately US$20.9 million. The acquisition, following Videology’s voluntary Chapter 11 restructuring proceedings, includes Videology’s technology platform, intellectual property and certain other assets of estimated net book value of US$5.3 million2. Over the past decade, Videology has emerged as a leading provider of software that empowers advertisers and publishers to use data to optimize campaigns and spend across digital platforms and television. The addition of Videology’s capabilities will be a further boost to Amobee’s omni-channel platform

Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform17.7.2018 12:00Pressemelding

Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY), one of the fastest growing hyperconverged infrastructure (HCI) vendors according to IDC, – with HCI revenue growing at almost twice the market growth rate in Q1 2018 (149.1% compared to 76.3%)—is further expanding its ThinkAgile portfolio to provide an innovative solution for customers who desire the agility of the public cloud and the security of a private cloud. To address this growing customer trend, Lenovo – together with Cloudistics – has developed the ThinkAgile CP Series composable cloud platform, a ‘cloud-in-a-box’ that offers all of the conveniences and ease-of-use of a public cloud environment secured behind the customer’s own data center firewall. Lenovo ThinkAgile CP Series – with fully-integrated infrastructure, application marketplace and end-to-end automation of software-defined network, compute and storage – delivers a turnkey cloud experience that can be easily and centrally managed from anywhere through a software-as-